Ketamine and Esketamine for Bipolar Depression
February 27, 2025 DOI: 10.64239/pi-qt7204
Summary
Ketamine and esketamine treatments for bipolar depression show a 40% response rate among patients receiving twice-weekly treatment, with only 13% achieving full remission. While no immediate manic switches were noted during the intensive treatment phase, 30% of patients experienced hypomania or mania during the maintenance phase, though most episodes were mild. It may be beneficial to involve family members in monitoring mood changes, especially for patients with severe mania or rapid cycling histories.
Study at a glance
| Population | patients with bipolar depression |
|---|---|
| Key finding | 40% of patients responded to twice-weekly ketamine or esketamine treatment for bipolar depression. |
Abstract
Ketamine and esketamine show promise in bipolar depression, with 40% of patients responding to twice-weekly treatment. Full remission occurs in 13%. No immediate manic switches occurred during intensive treatment, but 30% experienced hypomania/mania during maintenance phase. Most episodes were mild. Consider involving family members in monitoring mood changes. Patients with severe mania or rapid cycling history may not be ideal candidates.